Mayo Clinic researchers: family history identified as new risk factor for heartburn

August 24, 1999



Study raises possibility of 'heartburn gene'


ROCHESTER, MINN.-- Mayo Clinic researchers have concluded that family history, possibly through a genetic link, and obesity are major independent risk factors for heartburn and acid regurgitation, both symptoms of gastroesophageal reflux disease.

Upwards of 20 percent of American and European populations are estimated to experience heartburn or acid regurgitation at least once a week. Chronic heartburn and acid reflux may lead to Barrett's esophagus, which may evolve into esophageal cancer.

In one of the few population-based studies on this subject-- published recently in The American Journal of Medicine-- Mayo Clinic researchers went outside the laboratory to survey 1,524 residents of Olmsted County, Minn. Participants were asked if any members of their immediate family (parents, siblings or children) had significant heartburn or disease of the esophagus or stomach.

Those who responded affirmatively were twice as likely to report that they themselves experienced heartburn or acid regurgitation. Participants with a higher body mass index (obesity), a past history of cigarette smoking or a higher consumption of alcohol also were at increased risk for gastroesophageal reflux symptoms.

"That family history was discovered as a risk factor suggests that there may be a genetic component to gastroesophageal reflux disease," says G. Richard Locke III, M.D., a gastroenterologist who led the team of Mayo Clinic researchers. "The other risk factors do not explain the familial 'clustering' of this disorder."

Apart from this study, Dr. Locke noted that several case reports have been published that describe families with multiple members who have experienced various forms of gastroesophageal reflux disease in up to four generations.

"This disorder likely is a combination of nature and nurture," Dr. Locke says. "However, more research into the human genome is needed to determine if indeed there is a gene that passes gastroesophageal reflux disease from one generation to the next."

Dr. Locke and colleagues further note that obesity, smoking and alcohol use are well recognized risk factors for reflux as well as other diseases. "We still need to prove, however, that modifying these factors has an effect on reflux," he says. "That is the next step."

For more information on this study, see the June 1999 edition of The American Journal of Medicine, or the May 1999 edition of The American Journal of Gastroenterology.
-end-


Mayo Clinic

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.